title: [Minimal residual disease in pancreatic cancer--our first experiences].
abstract: BACKGROUND
  Pancreatic cancer is one of the most aggressive malignity with the statistically shown an upward trend and a very poor prognosis. The causes we follow up in the local recurrence and in the early dissemination, either through hematogenic or lymphogenic way. Conventional methods are not able to capture these cells, just the modern molecular-biological methods make possible to fix the so-called minimal residual disease, that is the presence of isolated tumor cells in the patient's body.
  
  
  METHODS
  The study included 52 patients operated on the Clinic of Surgery I. in the University Hospital Olomouc for pancreatic cancer in different stages. QRT-PCR method was determined expression of hTERT, EGFR 1 and CEA both in peripheral blood, portal blood, bone marrow, peritoneal lavage and the tumor itself.
  
  
  CONCLUSIONS
  The results of this pilot study demonstrated a high sensitivity and specificity of the PCR method for detection of circulating tumor cells in patients with pancreatic cancer, extending this methodology, we are able to provide prognostic value of minimal residual disease and its significance for the indication of radical surgery for pancreatic cancer.
authors.affiliation: I. chirurgická klinika FN a LF UP v Olomouci. dklos@seznam.cz
authors.forename: D
authors.initials: D
authors.lastname: Klos
authors.forename: M
authors.initials: M
authors.lastname: Lovecek
authors.forename: P
authors.initials: P
authors.lastname: Skalický
authors.forename: J
authors.initials: J
authors.lastname: Srovnal
authors.forename: M
authors.initials: M
authors.lastname: Kesselová
authors.forename: L
authors.initials: L
authors.lastname: Radová
authors.forename: M
authors.initials: M
authors.lastname: Hajdúch
authors.forename: C
authors.initials: C
authors.lastname: Neoral
authors.forename: R
authors.initials: R
authors.lastname: Havlík
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002272:Carcinoembryonic Antigen / Q000097:blood; D002277:Carcinoma / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D066246:ErbB Receptors / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D010190:Pancreatic Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
chemical_list: D002272:Carcinoembryonic Antigen; D066246:ErbB Receptors